Sponsor Dossier
Sun Pharma
Sponsor Dossier for Sun Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: AATORVASTATIN
- Brand: ABISART
- Brand: ACICLOVIR
- Brand: AMLODIPINE
- Brand: AMOXYCILLIN GENERICHEALTH
- Brand: AMPHOTERICIN LIPOSOMAL
- Brand: APO-DIAZEPAM
- Brand: ARIPENA
About
Sun Pharma is an Australian Private Company with ABN 17 110 871 826, registered in NSW. The entity is currently active and registered for GST.
Portfolio
Sun Pharma holds 115 brands on the ARTG, of which 49 are indexable. The company has 44 brands with Product Information on file, 9 brands with at least one PBS-listed item, 11 brands with PBAC outcomes on record, and 4 brands with AusPARs on record.
Therapeutic focus
— Neurology: 32 brands — Infectious Disease: 29 brands — Cardiology: 14 brands — Oncology: 14 brands — Endocrinology: 6 brands — Gastroenterology: 4 brands — Women's Health: 4 brands — Ophthalmology: 3 brands — Dermatology: 2 brands — Immunology: 2 brands — Psychiatry: 2 brands — Haematology: 1 brand — Pain & Anaesthesia: 1 brand — Urology: 1 brand
PBS footprint
Sun Pharma has 9 brands with at least one PBS-listed item. The latest PBS schedule date the portfolio touched is 1 May 2026.
Regulatory activity
Sun Pharma's latest PBAC outcome is dated 1 November 2025, with 11 brands holding PBAC outcomes on record. The most recent AusPAR is dated 8 March 2024, with 4 brands holding AusPARs on record.